表紙
市場調査レポート

医薬品市場調査レビュー 2015年

2015 Pharmaceuticals Research Review

発行 BCC Research 商品コード 224411
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
医薬品市場調査レビュー 2015年 2015 Pharmaceuticals Research Review
出版日: 2016年01月01日 ページ情報: 英文 137 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の癌ワクチン市場規模は2013年に45億米ドル、2014年に約40億米ドルに達しました。同市場は2014年から2019年にかけて1.3%のCAGRで推移し、2019年までに43億米ドルに達すると予測されています。世界の「沈黙の」がん市場規模は2013年に85億米ドル、2014年に90億米ドルに達しました。同市場は2014年から2019年にかけて8.5%のCAGRで推移し、2019年までに136億米ドルに達すると予測されています。世界のインクレチン製剤市場規模は2013年に118億米ドル、2014年に127億米ドルに達しました。同市場は2014年から2019年にかけて12.4%のCAGRで推移し、2019年までに228億米ドルに達すると予測されています。

当レポートでは、2015年における医薬品市場の全体的な市場発展動向を概括し、癌ワクチン、「沈黙の」癌の治療、インクレチン製剤、オーファンドラッグ、および感染症治療薬市場のレビューを提供しています。

第1章 序文

第2章 癌ワクチン:技術と世界市場

  • イントロダクション
  • エグゼクティブサマリー
  • 定義
  • 癌とその管理の歴史
  • 癌の分類
  • 癌の症状
  • リスク因子
  • 発癌物質
  • 市販の癌ワクチン
  • 有病率
  • 癌と免疫システム
  • 癌の分子生物学
  • 癌の病態生理学
  • 癌の予防
  • 癌の管理
  • 癌ワクチン

第3章 「沈黙の」癌の治療

  • イントロダクション
  • サマリー
  • 概要
  • 問題の増加
  • 市場ダイナミクス
  • 主な抗癌剤
  • 無症候性癌

第4章 インクレチン製剤:糖尿病治療薬市場および治療薬の開発

  • イントロダクション
  • エグゼクティブサマリー
  • 血糖管理に必要なインクレチン調合
  • 調剤・売上の動向
  • 地域シフト
  • 主な促進因子
  • 主な課題
  • 主な動向
  • 概要と市場予測
  • インクレチン適合分野に関するデータ
  • 標準的な糖尿病治療
  • 糖尿病のさらに詳しい説明
  • インクレチン療法
  • 市場情報
  • インクレチン市場における契約

第5章 世界のオーファンドラッグ (希少医薬品) 市場

  • イントロダクション
  • エグゼクティブサマリー
  • 概要
  • 各種オーファンドラッグ
  • 世界の希少疾患の定義
  • 希少医薬品法の展望と歴史
  • 米国の法律
  • 世界のオーファンドラック展望
  • 希少医薬品法の影響
  • オーファンドラッグ vs. 標準的な治療薬の違い
  • 希少医薬品法

第6章 世界の感染症治療薬市場

  • イントロダクション
  • サマリー
  • 世界の感染症診断、ワクチンおよび治療の状況
  • 世界の死因のトップ
  • 主な感染症
  • 感染症の歴史的影響
  • 感染症の治療
  • 世界の感染症診断市場
  • 診断検査の種類
  • 世界の感染症診断製品
  • 世界の感染症ワクチン市場
  • 世界の感染症医薬品市場
  • ワクチンの機会
  • 医薬品の機会
  • 遺伝子療法の登場

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM099E

REPORT HIGHLIGHTS

  • The global market for cancer vaccines totaled $4.5 billion in 2013 and reached nearly $4.0 billion in 2014. This market is expected to reach $4.3 billion by 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
  • The global market for "silent" cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a CAGR of 8.5% from 2014 to 2019.
  • The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a CAGR of 12.4% from 2014 to 2019.

REPORT SCOPE

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. These Research Reviews include portions of several market research reports that were published in 2015, and are an efficient way for market professionals to keep up with the general market developments of 2015.

Please note that page references in the text are to pages in the original, complete report, and do not reflect the actual page numbers in this Research Review.

This 2015 Pharmaceuticals Research Review includes excerpts from the following reports:

  • Cancer Vaccines: Technologies and Global Markets.
  • Therapeutics for 'Silent' Cancers.
  • Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
  • Global Markets for Orphan Drugs.
  • Global Markets for Infectious Disease Treatments

Table of Contents

CHAPTER 1 FOREWORD

CHAPTER 2 CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM173A)

  • INTRODUCTION
  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • EXECUTIVE SUMMARY
  • TABLE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
  • DEFINITIONS
  • HISTORY OF CANCER AND ITS MANAGEMENT
  • TABLE 2 HISTORY OF CANCER AND ITS MANAGEMENT
  • CLASSIFICATION OF CANCERS
  • CLASSIFICATION BY SITE OF ORIGIN
  • CLASSIFICATION BY TISSUE TYPE
    • Carcinoma
      • Adenocarcinoma
      • Squamous Cell Carcinoma
    • Sarcomas
    • Myeloma
    • Leukemias
    • Lymphomas
    • Mixed Types
  • CLASSIFICATION BY GRADE
  • SYMPTOMS OF CANCER
  • LOCAL SYMPTOMS
  • SYSTEMIC SYMPTOMS
  • SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS
  • RISK FACTORS
  • CANCER-CAUSING AGENTS
  • CHEMICAL CARCINOGENS
  • IONIZING RADIATION
  • VIRAL AND BACTERIAL INFECTIONS
  • GENETIC OR INHERITED CANCERS
  • HORMONAL CHANGES
  • IMMUNE SYSTEM DYSFUNCTION
  • COMMERCIALLY AVAILABLE CANCER VACCINES
  • LIVER CANCER
  • PROSTATE CANCER
    • Radical Retropubic Prostatectomy
    • Laparoscopic Prostatectomy
    • Radical Perineal Prostatectomy
    • Transurethral Resection of the Prostate
  • CERVICAL CANCER
  • PREVALENCE
  • TABLE 3 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)
  • INCIDENCE AND MORTALITY RATE
  • TABLE 4 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012
  • CANCER STATISTICS BY GEOGRAPHY
  • TABLE 5 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
  • TABLE 6 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
  • GLOBAL CANCER STATISTICS BY TYPE OF CANCER
  • TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)
  • TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)
  • TABLE 9 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)
  • VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY
  • TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012
  • TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012
  • TABLE 12 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012
  • CANCER AND THE IMMUNE SYSTEM
  • MOLECULAR BIOLOGY OF CANCER
  • CANCER PATHOPHYSIOLOGY
  • ONCOGENES
  • TUMOR SUPPRESSOR GENES
  • PREVENTION OF CANCER
  • MANAGEMENT OF CANCER
  • SURGERY
  • CHEMOTHERAPY
  • RADIATION THERAPY
  • TARGETED THERAPY
  • IMMUNOTHERAPY
  • HORMONAL THERAPY
  • BIOLOGICAL THERAPY
  • CANCER VACCINES
  • CLASSIFICATION OF CANCER VACCINES
    • Preventive (or Prophylactic) Vaccines
    • Therapeutic Vaccines
  • MANUFACTURING/CREATING VACCINES
  • TYPES OF CANCER VACCINES
    • Tumor Cell Vaccines
    • Cancer Stem Cell Vaccines
    • Peptide/Protein Vaccines
      • Antigen Vaccines
      • Anti-idiotype Vaccines
      • Heat Shock Protein Vaccines
      • DNA and Vector-Based Vaccines

CHAPTER 3 THERAPEUTICS FOR ''SILENT'' CANCERS (REPORT PHM169A)

  • INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • SUMMARY
  • TABLE 13 GLOBAL MARKET FOR ''SILENT'' CANCERS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ''SILENT'' CANCERS, 2013 AND 2019 (%)
  • OVERVIEW
  • CANCER: A GLOBAL PERSPECTIVE
  • GROWING PROBLEM
  • MARKET DYNAMICS
  • SOME LEADING ANTICANCER DRUGS
  • DRUG CATEGORIES
  • ASYMPTOMATIC CANCER
  • TELLTALE GENES
  • TUMOR MARKERS

CHAPTER 4 INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS (REPORT PHM162A)

  • INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • EXECUTIVE SUMMARY
  • INCRETINS FILL NEED FOR GLYCEMIC CONTROL
  • TRENDS IN DISPENSING AND SALES
  • TABLE 14 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
  • GEOGRAPHICAL SHIFTS
  • KEY DRIVERS
  • KEY CHALLENGES
  • KEY TRENDS
  • OVERVIEW AND MARKET FORECAST
  • FIGURE 4 THE INCRETIN EFFECT ILLUSTRATED
  • FIGURE 5 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
  • DATA ON WHERE INCRETINS FIT
  • FIGURE 6 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
  • FIGURE 7 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
  • FOR SOME, A GLP-1 FOCUS
  • TABLE 15 DIFFERENCES BETWEEN THE INCRETIN THERAPIES
  • STANDARD DIABETIC TREATMENTS
  • METFORMIN
  • SULFONYLUREAS (SU)
  • THIAZOLIDINEDIONE (TZD)
  • ALPHA-GLUCOSIDASE INHIBITORS
  • INSULIN TREATMENT
    • Long-Acting Insulin
    • Intermediate-Acting Insulin
    • Regular or Short-acting Insulin
    • Rapid-Acting Insulin
    • TABLE 16 ADVANTAGES TO ADDING INCRETIN THERAPY
  • OTHER NEW TREATMENTS
  • DIABETES FURTHER EXPLAINED
  • TYPES OF DIABETES
    • Type 1
    • Type 2
    • Gestational Diabetes
    • Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG)
  • CARE MODEL UPDATED WITH INCRETINS
  • CONDITIONS RELATED TO DIABETES
    • Obesity
    • FIGURE 8 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
    • Cardiovascular Disease
    • Pancreatitis
    • Cancer
    • TABLE 17 CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
    • Polycystic Ovary Syndrome
  • COMPLICATIONS AND COMORBIDITIES
  • TABLE 18 COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
  • INCRETIN THERAPIES
  • TABLE 19 COMMERCIALIZED INCRETIN THERAPY
  • GLP-1 RECEPTOR AGONISTS
  • COMMERCIALIZED GLP-1 RECEPTOR AGONISTS
    • Exenatide
    • Liraglutide
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
  • COMMERCIALIZED DPP-4 INHIBITORS 8
    • Linagliptin
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Alogliptin
    • Teneligliptin
    • Anagliptin
    • Gemigliptin
  • MARKET LANDSCAPE
  • TABLE 20 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
  • FIGURE 9 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
  • FIGURE 10 MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
  • FIGURE 11 MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
  • FIGURE 12 MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
  • DEALS IN THE INCRETIN MARKET
  • TABLE 21 MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT

CHAPTER 5 GLOBAL MARKETS FOR ORPHAN DRUGS (REPORT PHM038E)

  • INTRODUCTION
  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS REPORT
  • CONTRIBUTIONS OF THE REPORT AND FOR WHOM
  • SCOPE OF THE REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • EXECUTIVE SUMMARY
  • TABLE 22 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 ($ MILLIONS)
  • FIGURE 13 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 ($ MILLIONS)
  • OVERVIEW
  • DIFFERENT KINDS OF ORPHAN DRUGS
  • BIOLOGICAL ORPHAN DRUGS
  • CHEMICAL OR NON-BIOLOGICAL ORPHAN DRUGS
  • GLOBAL DEFINITIONS OF RARE DISEASES
  • U.S.
  • EU
  • TAIWAN
  • JAPAN
  • AUSTRALIA
  • TABLE 23 RARE DISEASES AND THEIR PREVALENCE
  • PERSPECTIVE AND HISTORY OF ORPHAN DRUG ACT
  • TABLE 24 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION
  • LEGISLATION IN THE U.S.
  • NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)
  • ORPHAN DRUG ACT
  • TABLE 25 AMENDMENTS OF U.S. ORPHAN DRUG ACT
  • GLOBAL PERSPECTIVE OF ORPHAN DRUGS
  • EUROPE
  • AUSTRALIA
  • SINGAPORE
  • JAPAN
  • TAIWAN
  • CANADA
  • BRAZIL
  • SOUTH KOREA
  • ISRAEL
  • RUSSIA
  • KAZAKHSTAN
  • TABLE 26 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN
  • IMPACT OF ORPHAN DRUG ACT
  • TABLE 27 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014
  • DIFFERENCE BETWEEN ORPHAN DRUGS VS NORMAL DRUGS
  • TABLE 28 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS
  • APPLICATION OF APPROVED ORPHAN DRUGS
  • TABLE 29 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE

CHAPTER 6 GLOBAL MARKETS FOR INFECTIOUS DISEASE TREATMENTS (REPORT PHM061C)

  • INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • SUMMARY
  • TABLE 30 GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
  • OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES AND TREATMENT
  • TOP GLOBAL CAUSES OF DEATH
  • TABLE 31 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)
  • MAJOR INFECTIOUS DISEASES
  • TABLE 32 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)
  • HISTORICAL IMPACT OF INFECTIOUS DISEASES
  • LEADING CAUSES OF GLOBAL DEATHS
    • Transmission of Infectious Diseases
  • LINKING INFECTIOUS DISEASE TO CANCER
  • TREATMENTS FOR INFECTIOUS DISEASES
  • PREVENTION
  • VACCINATION
    • WHO Global Vaccination Action Plan
    • FIGURE 15 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)
    • Challenges to Meet WHO Guidelines
    • GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
  • TYPES OF DIAGNOSTIC TESTING
  • FLUORESCENT IMMUNOASSAY (FIA)
    • Direct Fluorescent Antibody Testing (FA)
    • Indirect Fluorescent Antibody Testing (IFA)
  • ENZYME IMMUNOASSAY (EIA)
    • Basic EIA
    • Enzyme-Linked Immunosorbent Assay (ELISA)
  • GENE PROBE ANALYSIS
    • Polymerase Chain Reaction Amplification (PCR)
    • Nucleic Acid Amplification Test (NAT)
    • Transcription-Mediated Amplification (TMA)
    • Nucleic Acid Sequence-Based Amplification (NASBA)
    • GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 33 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • GLOBAL INFECTIOUS DISEASE VACCINE MARKET
  • TABLE 34 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET
  • TABLE 35 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • VACCINE OPPORTUNITIES
  • CHILDHOOD DISEASES
  • GLOBAL HUMANITARIAN AGENCIES
  • PHARMACEUTICAL OPPORTUNITIES
  • THE EMERGENCE OF GENE THERAPY
  • MERGERS AND ACQUISITIONS
  • TABLE 36 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS)

LIST OF TABLES

  • TABLE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 2 HISTORY OF CANCER AND ITS MANAGEMENT
  • TABLE 3 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)
  • TABLE 4 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012
  • TABLE 5 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
  • TABLE 6 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
  • TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)
  • TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)
  • TABLE 9 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)
  • TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012
  • TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012
  • TABLE 12 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012
  • TABLE 13 GLOBAL MARKET FOR ''SILENT'' CANCERS, THROUGH 2019 ($ MILLIONS)
  • TABLE 14 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 DIFFERENCES BETWEEN THE INCRETIN THERAPIES
  • TABLE 16 ADVANTAGES TO ADDING INCRETIN THERAPY
  • TABLE 17 CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
  • TABLE 18 COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
  • TABLE 19 COMMERCIALIZED INCRETIN THERAPY
  • TABLE 20 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
  • TABLE 21 MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT
  • TABLE 22 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 RARE DISEASES AND THEIR PREVALENCE
  • TABLE 24 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION
  • TABLE 25 AMENDMENTS OF U.S. ORPHAN DRUG ACT
  • TABLE 26 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN
  • TABLE 27 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014
  • TABLE 28 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS
  • TABLE 29 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE
  • TABLE 30 GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)
  • TABLE 32 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)
  • TABLE 33 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS)

LIST OF FIGURES

  • FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ''SILENT'' CANCERS, 2013 AND 2019 (%)
  • FIGURE 3 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
  • FIGURE 4 THE INCRETIN EFFECT ILLUSTRATED
  • FIGURE 5 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
  • FIGURE 6 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
  • FIGURE 7 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
  • FIGURE 8 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
  • FIGURE 9 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
  • FIGURE 10 MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
  • FIGURE 11 MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
  • FIGURE 12 MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
  • FIGURE 13 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
  • FIGURE 15 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)
Back to Top